C12N 2770/18011
Comoviridae
C12N2770/18011 (Comoviridae) appears on 39 US grants and 77 published applications in this corpus.
Search patents in C12N- Granted patents
- 39
- Published applications
- 77
- Assignees
- 56
- Inventors
- 197
- Latest grant
- 11 Nov 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 1 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 2 | 0 |
| 2006 | 2 | 1 |
| 2007 | 1 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 1 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 1 |
| 2014 | 1 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 1 | 1 |
| 2018 | 2 | 2 |
| 2019 | 1 | 2 |
| 2020 | 1 | 2 |
| 2021 | 0 | 9 |
| 2022 | 5 | 13 |
| 2023 | 4 | 13 |
| 2024 | 10 | 12 |
| 2025 | 5 | 12 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/18022New viral proteins or individual genes, new structural or functional aspects ofIndexing code22
- C12N 2770/18034Use of virus or viral component as vaccineIndexing code20
- C12N 2770/18023Virus like particles [vlp]Indexing code13
- C12N 2770/18071Demonstrated in vivo effectIndexing code10
- C12N 2770/18041Use of virus, viral particle or viral elements as a vectorIndexing code4
- C12N 2770/18051Methods of production or purification of viral materialIndexing code3
- C12N 2770/18021Viruses as suchIndexing code2
- C12N 2770/18031Uses of virus other than therapeutic or vaccineIndexing code1
All 12 subgroupsShow fewer
Recent patents
- Cancer immunotherapy using virus particles and immune checkpoint therapy11 Nov 2025US 12,465,624 B2Case Western Reserve University
- Conserved region T cell vaccines for coronavirus and methods of use22 Jul 2025US 12,364,750 B1Beth Israel Deaconess Medical Center, Inc.
- Recombinant multivalent influenza viruses6 May 2025US 12,290,562 B2Wisconsin Alumni Research Foundation (WARF)
- Compositions and methods of mRNA vaccines against novel coronavirus infection22 Apr 2025US 12,280,105 B2RNAimmune, Inc.
- Sustained release cowpea mosaic virus or virus-like particle therapeutic constructs for the treatment of cancer7 Jan 2025US 12,186,279 B2Case Western Reserve University
- Engineered Plant Virus-Based Nanoparticles and Intravenous Formulations Thereof for Autoimmune Therapy16 Jul 2026US 2026/0199518 A1
- Cancer immunotherapy using virus particles and immune checkpoint therapy25 Jun 2026US 2026/0174813 A1Case Western Reserve University
- S100a9 vaccines for cancer and atherosclerosis30 Oct 2025US 2025/0332234 A1The Regents of the University of California
- Cancer therapy23 Oct 2025US 2025/0325608 A1The Regents of the University of California
- Coronavirus vaccine31 Jul 2025US 2025/0242059 A1BioNTech SE
Most cited
By later US patents
- Modified plant viruses as vectors17US 5,874,087 AAxis Genetics PLC · 1999
- Mouse-adapted SARS-CoV-2 viruses and methods of use thereof12US 11,225,508 B1The University of North Carolina at Chapel Hill · 2022
- Disease resistance in vitis12US 6,232,528 B1The United States of America as represented by the Secretary of Agriculture · 2001
- Modified plant viruses as vectors10US 6,110,466 AAxis Genetics PLC · 2000
- Coronavirus vaccine9US 11,547,673 B1BioNTech SE · 2023